Claret Medical Announces Financing to Support Commercialization of Sentinel Cerebral Protection System

October 23, 2017—Claret Medical announced that it has closed on a Series C financing of $14.5 million that will support market-access programs, research and development for next-generation products, and expansion of the controlled commercial release of the company’s Sentinel cerebral protection system in the United States.

In June, the company announced that the Sentinel device has been cleared by the US Food and Drug Administration for used in transcatheter aortic valve replacement procedures.

Since the company’s Series B round in 2014, Claret Medical has pursued a structured study program of the Sentinel device involving three randomized studies and more than 2,300 patients, including the United States SENTINEL pivotal trial and a large-scale, real-world trial. The Sentinel has been commercialized in Europe, selected Asia Pacific countries, and the United States.

The financing was led by Lightstone Ventures, with participation from existing investors Easton Capital, HealthCor Partners, Incept LLC, and Sante Ventures.